Answers are grounded in this paper and cite their sources.
Tremendous advancements in proteolysis targeting chimera (PROTAC) technology have been made in recent years. However, whether a covalent inhibitor-based PROTAC can be developed remains controversial. Here, we successfully developed chimeric degraders based on covalent inhibitors to degrade BTK and BLK kinases, demonstrating that covalent inhibitor-based PROTACs are viable and useful tools.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: